Medical Product Outsourcing

Cardiovascular

J&J's Biosense Webster Reveals Positive Dual-Energy Ablation Results

Trial results from the SmartfIRE trial of the Dual Energy Thermocool Smarttouch SF catheter for AFib.

Sam Brusco, Associate Editor 04.09.24

Cardiovascular

J&J's Biosense Webster Submits Varipulse Pulsed Field Ablation for FDA Approval

The submission was supported by data from the company’s admIRE study.

Sam Brusco, Associate Editor 03.25.24

Cardiovascular

J&J's Abiomed Recalls Impella Left-Sided Heart Pumps for Perforation Risk

The pump catheter may perforate the wall of the heart’s left ventricle.

Sam Brusco, Associate Editor 03.21.24

Surgical

J&J MedTech, NVIDIA Team Up to Scale AI for Surgery

The partnership aims to increase access to real-time analysis and global availability of AI algorithms.

Sam Brusco, Associate Editor 03.19.24

Cardiovascular

J&J's Biosense Webster Nabs EU Nod for Varipulse Pulsed Field Ablation

Varipulse’s safety and efficacy were investigated in the inspIRE trial of 186 patients in Canada and Europe.

Sam Brusco, Associate Editor 02.29.24

Cardiovascular

J&J's Biosense Webster Starts Enrollment in Laminar LAA Elimination Trial

The trial will compare Laminar LAAX’s safety and efficacy to available LAA closure devices.

Sam Brusco, Associate Editor 02.27.24

Cardiovascular

J&J's Biosense Webster Supports 2 More Pulsed Field Ablation Studies

The VIRTUE and POLARIS studies are further evaluating the company's Varipulse PFA system.

Sam Brusco, Associate Editor 02.08.24

Cardiovascular | Neurological

J&J's CERENOVUS Launches Next-Gen Catheter for Revascularization of Acute Ischemic Stroke

The CereGlide 71 intermediate catheter features TruCourse to increase flexibility and improve navigation and access to clots.

Sam Brusco, Associate Editor 02.07.24

Cardiovascular

J&J's Biosense Webster Shares Late-Breaking Data on Varipulse PFA

Final results from the inspIRE study demonstrated 80% freedom from atrial arrhythmia recurrence at 12 months.

Sam Brusco, Associate Editor 02.05.24

LivaNova Hires J&J MedTech Exec Vladimir Makatsaria as CEO

Makatsaria will take office on March 1, succeeding interim CEO and board chair Bill Kozy.

Sam Brusco, Associate Editor 02.05.24

Cardiovascular

J&J's Biosense Webster Treats Initial Patients in SmartPulse Dual-Energy Ablation Trial

Dual Energy STSF is a focal, contact force-sensing catheter that can deliver both RF and PFA energy.

Sam Brusco, Associate Editor 12.15.23

Surgical

Integra to Buy J&J's Acclarent, Strengthening ENT Biz

Acclarent will become part of Integra’s Codman Specialty Surgical division.

Sam Brusco, Associate Editor 12.13.23

J&J Presents Its Strategy, Pipelines and Financial Outlook

The company met with the investment community at the NYSE to highlight key drivers for growth and value creation.

Charles Sternberg, Associate Editor 12.06.23

Cardiovascular | Surgical

J&J MedTech Acquires LAA Elimination Firm Laminar for $400 Million

Laminar uses rotational motion to eliminate the LAA, unlike current catheter-based procedure devices.

Sam Brusco, Associate Editor 11.30.23

Surgical

J&J's Ethicon Earns EU Approval for Ethizia Hemostatic Sealing Patch

The company said in 80% of clinical trial patients studied, Ethizia stopped bleeding in 30 seconds.

Sam Brusco, Associate Editor 11.15.23

Surgical

Chinese Regulators Approve J&J MedTech's MONARCH Platform for Bronchoscopy

The MONARCH Platform is the first MI, robotic-assisted technology approved for bronchoscopy in a country with a significant lung cancer burden.

Michael Barbella, Managing Editor 11.14.23

J&J MedTech Targets Late 2024 for Ottava Robot IDE Submission

The four-armed Ottava robot, integrated into a standard-size surgical table, will use Ethicon's instrumentation.

Sam Brusco, Associate Editor 11.07.23

Surgical

J&J's Ethicon Debuts AI-Powered Surgical Simulation Tool

The skills training platform is intended for general, gynecological, and laparoscopic surgeons.

Sam Brusco, Associate Editor 11.06.23

Cardiovascular

J&J's Biosense Webster Touts Positive Data for QDOT MICRO Catheter

QDT MICRO catheter treatment was shown to improve control of AFib, relief of symptoms, and overall quality of life.

Sam Brusco, Associate Editor 11.03.23

J&J MedTech Top Exec Ashley McEvoy Steps Down

McEvoy is departing to pursue other opportunities; Tim Schmid will assume her position.

Sam Brusco, Associate Editor 10.24.23

J&J Marks New Era With Updated Brand

Moving forward, the company’s MedTech and Pharmaceutical segments will be more connected to the Johnson & Johnson brand.

Michael Barbella, Managing Editor 09.14.23

Cardiovascular

J&J's Abiomed Comments on Another Impella Recall Over Blood Clot Risk

Impella RP Flex catheters’ IFU doesn’t appropriately address precautions for anticoagulation time below recommended value.

Sam Brusco, Associate Editor 08.18.23

Cardiovascular

J&J's Biosense Webster Nets FDA Approval for AFib Ablation Products

The AFib ablation products received approval for use in a workflow without fluoroscopy.

Sam Brusco, Associate Editor 08.04.23

Cardiovascular

J&J's Biosense Webster Launches OPTRELL Mapping Catheter

Contains TRUEref technology for mapping of complex cardiac arrhythmias.

Sam Brusco, Associate Editor 07.25.23

Cardiovascular

J&J's Abiomed Issues Device Correction for Impella Heart Pump Over TAVR Complications

There’s potential risk of unintentional interaction of the Impella motor housing with the distal stent of a TAVR.

Sam Brusco, Associate Editor 07.21.23

Surgical

J&J's Ethicon Recalls Megadyne Electrodes Over Burn Risk to Patients

A J&J MedTech spokesperson reached out to MPO with an update on the recall.

Sam Brusco, Associate Editor 07.12.23

Boston Scientific Elects J&J, Verily Execs to Board

Dr. Jessica Mega is the co-founder of Verily; Susan Morano was a J&J MedTech VP.

Sam Brusco, Associate Editor 06.27.23

J&J's Biosense Webster Names Jasmina Brooks as President

Brooks is a nine-year veteran of Biosense Webster and was most recently VP of global strategic marketing for the company.

Sam Brusco, Associate Editor 05.18.23

J&J Exec Ashley McEvoy Named AdvaMed's New Chairman

McEvoy leads J&J’s $27 billion medtech business.

Sam Brusco, Associate Editor 03.21.23

Surgical

CMR Surgical, J&J Team Up on Surgical Robotics

Will help further accelerate access to minimally invasive robotic surgery in select European and South American markets.

Sam Brusco, Associate Editor 11.29.22

Ahmet Tezel Named Global Head of MedTech Innovation and R&D at J&J

Tezel has held various executive positions in research, development, and tech transfer across numerous medical specialties and companies.

Michael Barbella, Managing Editor 11.08.22

J&J Vision Releases Tecnis Symfony OptiBlue IOL

The presbyopia-correcting intraocular lens contains InteliLight technology.

Sam Brusco, Associate Editor 09.29.22

Chronic Disease

J&J Vision's Overnight Lenses for Myopia Management Earn FDA Nod

AcuVue Ability ortho-k lenses are worn overnight to temporarily lower refractive error.

Sam Brusco, Associate Editor 09.28.22

J&J Vision Rolls Out AcuVue Oasys Max 1-Day Contact Lenses

Features TearStable tear-film stability and OptiBlue blue-violet light filter.

Sam Brusco, Associate Editor 09.13.22

Surgical

J&J's Acclarent Earns FDA Nod for TruDi Shaver Blade

Designed for navigated accuracy during ENT procedures.

Sam Brusco, Associate Editor 08.03.22

FDA OKs J&J Vision's AcuVue Oasys Max 1-Day Contact Lenses

The lenses aim to help provide all-day comfort and visual clarity amid today’s modern lifestyles.

Sam Brusco, Associate Editor 06.15.22

Surgical

J&J's Ethicon Releases Echelon 3000 Stapler in U.S.

The digitally-enabled device provides one-handed powered articulation.

Sam Brusco, Associate Editor 06.06.22

Surgical

J&J Ethicon's Monarch Platform Cleared by FDA for Endourological Procedures

Enables urologists to reach and visualize areas within the kidney with precision and control.

Charles Sternberg, Associate Editor 05.02.22

Appeals Court Orders J&J to Pay $302M in Pelvic Mesh Case

Judges trim $42 million from original penalty but uphold company's guilt in deceptive marketing practices.

Michael Barbella, Managing Editor 04.14.22

FDA Approves J&J Vision's ACUVUE Theravision Drug-Eluting Contact Lenses

Contains the antihistamine ketotifen to combat allergic eye itch.

Sam Brusco, Associate Editor 03.02.22

J&J Medical Devices Biz Achieves Double-Digit Growth in 2021

Johnson & Johnson franchise reports $27.1 billion in 2021 sales.

Sam Brusco, Associate Editor 01.25.22

J&J's Acclarent Launches AI-Powered ENT Navigation Tech

TruDi is the first and only ENT navigation system that leverages AI-powered technology with the launch of TruSeg and TruPath.

PR Newswire 01.19.22

Surgical

FDA Approves J&J's MENTOR MemoryGel BOOST Breast Implant

Implant provides natural feel patients desire with increased form stability.

Sam Brusco, Associate Editor 01.13.22

Digital Health | Software & IT | Surgical

Surgical

FDA Approves J&J Vision's TECNIS Synergy, Synergy Toric II IOLs

Next-generation presbyopia-correcting intraocular lens (PCIOL) also approved in Canada.

Sam Brusco, Associate Editor 05.07.21

FOLLOW:

Search Results for 'j&j'

April 2024

follow us